Study S001184
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)
Registration
Registered primary outcomes
- Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 26 Weeks]
Linked records (4)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0020285 | Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Yu M, Diabetes, obesity & metabolism | 2016 | Other trial | PMID 26691396DOI | cites ClinicalTrials.gov:NCT01624259; registry reference DERIVED:26691396 |
| R0025090 | Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Boustani MA, Diabetes, obesity & metabolism | 2016 | Other trial | PMID 27161178DOI | cites ClinicalTrials.gov:NCT01624259; registry reference DERIVED:27161178 |
| R0020934 | Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Dungan KM, Lancet (London, England) | 2014 | Randomized trial | PMID 25018121DOI | cites ClinicalTrials.gov:NCT01624259; registry reference DERIVED:25018121 |
| R0049819 | Dulaglutide Noninferior to Liraglutide for Glycemic Control in Patients with T2DM Maria Vinall, MD Conference Express | 2014 | Other trial | DOI | cites ClinicalTrials.gov:NCT01624259 |